... WhatsApp

Diabetes Medication May Lower Risk of Liver Cancer and Death

You are here >> Home > Latest Updates > Liver Cancer Updates > Diabetes Medication…

Diabetes Medication May Lower Risk of Liver Cancer and Death

Liver cancer is becoming more common, especially in people with metabolic dysfunction-associated steatotic liver disease (MASLD), often called fatty liver disease, and type 2 diabetes. Both conditions together greatly increase the risk of hepatocellular carcinoma (HCC), the most common type of liver cancer.

A large international study looked at whether medicines known as GLP-1 receptor agonists (GLP-1RAs)—commonly used to treat diabetes—could also reduce the risk of liver cancer. These drugs, which include treatments like semaglutide and liraglutide, are already known for helping with blood sugar control and weight loss.

The study compared more than 300,000 patients with MASLD and type 2 diabetes. Half used GLP-1RAs, while the other half did not.

The results were encouraging:
– Patients using GLP-1RAs had a 36% lower risk of liver cancer.
– They also had a 63% lower risk of death from any cause.

These findings suggest that GLP-1RAs may not only help manage diabetes and weight but also protect against serious complications like liver cancer.

Doctors are still learning how best to use these medicines for liver health, but this research points to a possible dual benefit—metabolic control and cancer prevention. Patients with diabetes and fatty liver disease may want to discuss with their doctors whether a GLP-1RA is a good option for them.

Rate this post

Exclusive Health Tips and Updates

Dr Harsh Shah - GI & HPB Oncosurgeon in Ahmeadbad
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.